Ocugen, Inc.
OCU400
Retinitis Pigmentosa
Resolved
103days ago
Phase 1 readout · Mar 26, 2026
What's at stake
Phase 1 trial results for OCU400 in Retinitis Pigmentosa are due Mar 26, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“OCU400 demonstrated a durable improvement in visual function (LLVA) in all evaluable treated subjects at 3 Yr when compared to untreated eyes Mean Change in LLVA (ETDRS Letters) from Baseline Results from Phase 1/2 Study Improvement in visu”